Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
- 1 April 2007
- journal article
- review article
- Published by Oxford University Press (OUP)
- Vol. 83 (978), 251-260
- https://doi.org/10.1136/pgmj.2006.052688
Abstract
Targeted biologic therapies have revolutionised treatment of immune-mediated inflammatory diseases (IMIDs) due to their efficacy, speed of onset and tolerability. The discovery that clinically unrelated conditions, such as rheumatoid arthritis and Crohn's disease, share similar immune dysregulation has led to a shift in the management of IMIDs from one of organ-based symptom relief to mechanism-based treatment. The fact that anticytokine therapy has been effective in treating multiple orphan inflammatory conditions confirms the IMID paradigm. In this review we examine the biologic agents currently licensed for use in the US and Europe: infliximab, etanercept, adalimumab, rituximab, abatacept, anakinra, alefacept and efalizumab. We also discuss the rationale behind the management of IMIDs using rheumatoid arthritis, Crohn's disease, psoriasis and psoriatic arthritis as examples. For the medical profession, IMID represents a breakthrough in the way pathology is classified. In this burgeoning era of biologic therapy the prospect of complete disease remission is conceivable.Keywords
This publication has 91 references indexed in Scilit:
- Prevalence and Treatment of Psoriasis in the United KingdomArchives of Dermatology, 2005
- Psoriasis—recent advances in understanding its pathogenesis and treatmentJournal of the American Academy of Dermatology, 2005
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseThe New England Journal of Medicine, 2004
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Crohn's diseaseThe Lancet, 2002
- Cytokines and autoimmunityNature Reviews Immunology, 2002
- Cost of Illness of Crohn??s DiseasePharmacoEconomics, 2002
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987